Lumata Health Secures $23 Million Series B to Expand Access and Adherence to Vision-Saving Care

March 05, 2025 at 08:00 AM EST

Round Led by LRVHealth, McKesson Ventures, and Cencora Ventures

Lumata Health, the leader in personalized support for patients with vision-threatening chronic eye diseases, today announced that it has raised $23 million in Series B funding to accelerate its mission of eliminating preventable vision loss, bringing its total raised since inception to $36 million. The round was co-led by LRVHealth, McKesson Ventures, and Cencora Ventures, with participation from existing investors including Cortado Ventures. The investment will enable Lumata to meet growing demand and further enhance the data-driven technology powering its patient adherence solutions.

Vision loss is a growing health crisis, with the prevalence of sight-threatening conditions such as glaucoma, diabetic retinopathy, and age-related macular degeneration expected to double in the coming decades. Although effective pharmacological treatments exist, systemic barriers continue to delay or prevent timely care for millions of patients. Lumata Health’s platform addresses these challenges by combining predictive analytics with personalized interventions—recently demonstrating that up to 800 additional vision-saving eye injections are delivered annually for every 1,000 participating patients. This proactive model not only preserves sight but also significantly reduces long-term healthcare costs associated with vision loss.

“We are thrilled to partner with investors who share our vision for a smarter, more effective approach to preventing blindness from chronic eye diseases,” said Landon Grace, CEO of Lumata Health. “This investment will allow us to continue scaling our data-driven approach to ensuring access and adherence to vision-saving treatments for the millions of people in the U.S. with these conditions.”

Over the past three years, Lumata has successfully partnered with eye care providers across the country, including the five largest national and regional eye care networks. These collaborations have fueled rapid growth and have demonstrated Lumata’s effectiveness in improving treatment adherence, enhancing patient satisfaction, and removing barriers to care. The participation of McKesson Ventures and Cencora Ventures in this round highlights the significant value Lumata brings to both practices and patients, and their expertise will further accelerate Lumata’s ability to deliver personalized care at scale.

“With millions of Americans at risk of preventable blindness, we’re investing in Lumata Health because it is uniquely positioned to drive meaningful change at scale,” said Ellen Herlacher, Partner at LRVHealth. “By combining advanced technology, predictive analytics, and compassionate care, the company is reshaping how chronic eye diseases are managed and ensuring that more patients retain their vision for years to come.”

“What impressed us most is Lumata’s potential to reduce overall healthcare costs while also generating significant value for ophthalmology practices,” added Michelle Snyder, Partner at McKesson Ventures. “Their proactive, end-to-end solution not only improves patient outcomes, it creates a win-win scenario for everyone involved in the care continuum.”

“As more specialty medicines reach the market, solutions designed to help patients start and stay on their prescribed treatment regimen are increasingly important,” said Jason Dinger, Senior Vice President of Strategic Execution at Cencora Ventures. “Lumata’s blend of technology and tailored support enables greater patient engagement and improved adherence to providers’ treatment plans.”

About Lumata Health

Founded in 2017 by Dr. Stephen Fransen, an ophthalmologist with over 30 years of experience, Lumata Health is powered by hundreds of certified ophthalmic care coaches, data scientists, and healthcare executives dedicated to ending preventable blindness. Through a human-led, technology-driven care management platform, Lumata partners with physicians, payers, and pharmaceutical manufacturers to provide tailored interventions that improve clinical outcomes and patient satisfaction while generating additional revenue and reducing downstream healthcare costs. To learn more, visit lumatahealth.com.